Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900
Debt
Debt-to-Equity Ratio-29.71
Current Ratio4.11
Quick Ratio3.64
Price-To-Earnings
Trailing P/E Ratio-4.55
Forward P/E Ratio-3.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$223.33 million
Price / Sales10.27
Cash FlowN/A
Price / CashN/A
Book Value$4.58 per share
Price / Book9.12
Profitability
EPS (Most Recent Fiscal Year)($9.17)
Net Income$-496,120,000.00
Net Margins-180.29%
Return on Equity-285.30%
Return on Assets-69.53%
Miscellaneous
Employees715
Outstanding Shares54,910,000
Market Cap$2.36 billion
TESARO (NASDAQ:TSRO) Frequently Asked Questions
What is TESARO's stock symbol?
TESARO trades on the NASDAQ under the ticker symbol "TSRO."
How were TESARO's earnings last quarter?
TESARO Inc (NASDAQ:TSRO) announced its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.66) by $0.38. The biopharmaceutical company earned $57.21 million during the quarter, compared to analyst estimates of $65.50 million. TESARO had a negative net margin of 180.29% and a negative return on equity of 285.30%. TESARO's revenue was up 94.2% on a year-over-year basis. During the same quarter last year, the business earned ($2.82) earnings per share. View TESARO's Earnings History.
When is TESARO's next earnings date?
How can I listen to TESARO's earnings call?
TESARO will be holding an earnings conference call on Thursday, November 1st at 4:15 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8778535334.
What price target have analysts set for TSRO?
20 analysts have issued 12 month target prices for TESARO's shares. Their predictions range from $38.00 to $160.00. On average, they expect TESARO's stock price to reach $78.4211 in the next twelve months. This suggests a possible upside of 87.8% from the stock's current price. View Analyst Price Targets for TESARO.
What is the consensus analysts' recommendation for TESARO?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TESARO in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TESARO.
What are Wall Street analysts saying about TESARO stock?
Here are some recent quotes from research analysts about TESARO stock:
- 1. Cantor Fitzgerald analysts commented, "We hosted Tesaro management (Lonnie Moulder, CEO and Mary Lynne Hedley, President & COO) at our investor dinner at Cantor Global Healthcare Conference. We think that management remain upbeat around the Zejula launch and progress in the company’s IO pipeline programs. Our thesis (click here) continues to be that expectations remain low for the company, and we see many events and milestones that remain not appreciated at the current valuation. Our dinner discussions were almost evenly split between the Zejula opportunity and IO programs." (10/1/2018)
- 2. Cann analysts commented, "The positive news that the JASPER study of Zejula in NSCLC is progressing to stage 2 follows positive pre-clinical data presented for Zejula in combination with anti-PD1/ anti-PD-L1 earlier this year. The JASPER data to-date provide preliminary evidence that the combination of anti-PD-1 antibody could be active as a first- line treatment for patients with non-small cell lung cancer and high levels of PD-L1. The NSCLC setting is a large market opportunity. Based on the stage and timing of JASPER, we have not included any revenue expectations in our model at this time for the NSCLC setting, but believe it offers the potential for meaningful upside for Tesaro." (9/4/2018)
- 3. According to Zacks Investment Research, "TESARO reported dismal second-quarter results, missing estimates on both counts. Its drug, Zejula has performed well since its approval in early 2017, gaining lead in U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. The company has lowered sales guidance for the drug in its Q2 earnings call. TESARO’s shares have underperformed the industry so far this year." (8/8/2018)
- 4. HC Wainwright analysts commented, "Updates to Varubi’s Label; Reiterate Buy and $158 Price Target Prescribing information update, no products being recalled. After the close on January 12, TESARO announced that it has updated the Varubi injectable emulsion package insert in collaboration with the FDA. The changes to the label include modifications to the Contradictions, Warnings and Precuations, and Adverse Reactions section to inclde anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with the use of Varubi injectable emulsion. The company indicated that anaphylaxis, anaphylactic shock and other hypersensitivity reactions have been reported in the postmarketing setting, with some cases requiring hospitalization. These side effects were noted during or soon after the infusion of Varubi, with most reactions observed during the first few minutes of administration." (1/12/2018)
Are investors shorting TESARO?
TESARO saw a increase in short interest in September. As of September 14th, there was short interest totalling 14,289,983 shares, an increase of 15.3% from the August 31st total of 12,395,903 shares. Based on an average daily trading volume, of 2,408,113 shares, the days-to-cover ratio is presently 5.9 days. Currently, 37.3% of the shares of the company are sold short. View TESARO's Current Options Chain.
Who are some of TESARO's key competitors?
Some companies that are related to TESARO include Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Valeant Pharmaceuticals (VRX), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Catalent (CTLT), SAGE Therapeutics (SAGE), Amarin (AMRN), Dr.Reddy's Laboratories (RDY) and Amneal Pharmaceuticals (AMRX).
Who are TESARO's key executives?
TESARO's management team includes the folowing people:
- Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 61)
- Dr. Mary Lynne Hedley, Co-Founder, Pres, COO & Director (Age 55)
- Mr. Timothy R. Pearson, Exec. VP & CFO (Age 50)
- Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 58)
- Mr. Orlando Oliveira, Sr. VP & GM of International (Age 42)
Who are TESARO's major shareholders?
TESARO's stock is owned by many different of retail and institutional investors. Top institutional investors include State of New Jersey Common Pension Fund D (0.51%), Mizuho Securities USA LLC (0.12%), Capital Impact Advisors LLC (0.08%), Seven Eight Capital LP (0.04%), Bank of Montreal Can (0.01%) and New Jersey Better Educational Savings Trust (0.01%). Company insiders that own TESARO stock include Arnold L Oronsky, David M Mott, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Joseph L Farmer, Lawrence M Alleva, Leon O Moulder Jr, Martin H Jr Huber, Mary Lynne Hedley, Orlando Oliveira, Peter J Barris and Timothy R Pearson. View Institutional Ownership Trends for TESARO.
Which major investors are selling TESARO stock?
TSRO stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold TESARO company stock in the last year include Arnold L Oronsky, Grant C Bogle, Joseph L Farmer, Lawrence M Alleva, Martin H Jr Huber, Mary Lynne Hedley, Orlando Oliveira and Timothy R Pearson. View Insider Buying and Selling for TESARO.
Which major investors are buying TESARO stock?
TSRO stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Mizuho Securities USA LLC, Seven Eight Capital LP, Capital Impact Advisors LLC and New Jersey Better Educational Savings Trust. Company insiders that have bought TESARO stock in the last two years include David M Mott, Enterprise Associates 13 L New, Leon O Moulder Jr and Peter J Barris. View Insider Buying and Selling for TESARO.
How do I buy shares of TESARO?
Shares of TSRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TESARO's stock price today?
One share of TSRO stock can currently be purchased for approximately $41.75.
How big of a company is TESARO?
TESARO has a market capitalization of $2.36 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. TESARO employs 715 workers across the globe.
What is TESARO's official website?
How can I contact TESARO?
TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.
MarketBeat Community Rating for TESARO (NASDAQ TSRO)
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
